Objective To investigate the efficacy and safety of rituximab on patients with thrombotic thrombo-cytopenic purpura (TTP) .Methods According to diagnosis and effect criteria of hematopathy ,28 cases meeting the diagnostic criteria of TTP were divided into treating group and control group .12 patients were received ritux-imab and plasmapheresis ,and the other 16 patients treated with plasmapheresis are in the control group .Results The effective rate in the treatment group was 91 .67% and 68 .75% in the control group .There was significant difference between two groups ( P<0.05 ) .The speed of the ascension of platelet was significantly faster than the control group on 3 ,5 and 12 days ( P< 0.05 ) but not on 21and 28 days after treatment ( P> 0.05 ) .After 12 months ,the recurrence rate was 9.09% in the treatment group and 54.55% in control group with a significant difference between the two groups (P<0.05) .Conclusion Therapy with rituximab was effective and well tolera-ted for patients with TTP .%目的：评价利妥昔单抗联合血浆置换治疗特发性血栓性血小板减少性紫癜（TTP）的疗效及安全性。方法符合诊断标准的特发性TTP患者28例，2010年1月至2013年1月在我院确诊的特发性TTP患者为治疗组12例，行利妥昔单抗联合血浆置换治疗，既往确诊的特发性TTP患者为对照组16例，仅给予血浆置换治疗。结果治疗组有效率为91.67％，对照组为68．75％，差异有统计学意义（P＜0.05），治疗组血小板在治疗后第3、5、12天后数值上升速度明显快于对照组，差异有统计学意义（P＜0.05），第21、28天，差异无统计学意义（P＞0.05）；随访12月，治疗组复发率9.09％，对照组为54.55％，差异有统计学意义（P＜0.05）。结论利妥昔单抗联合血浆置换可有效治疗特发性TTP ，且耐受性良好。
展开▼
